This study looks at how well a medicine called JNJ-79635322 works for people with Relapsed or Refractory Multiple Myeloma (RRMM). Multiple Myeloma is a type of cancer that affects plasma cells, a kind of white blood cell. If the cancer returns after treatment, it's called "relapsed." If it doesn't respond to treatment, it's "refractory." To join this study, you must have tried at least three other treatments already. These treatments usually include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody (mAb). You also need to have a good performance status, which means you should be relatively fit and able to do daily activities without too much trouble. You cannot join if you have allergies to the study drug or if you have other serious medical conditions.

• The study requires participants to stop any other cancer treatments before starting.
• Participants should not have had major surgery 2 weeks before joining.
• Individuals with active brain involvement from cancer cannot participate.